The motion claimed that Ranbaxy had failed to comply FDA standards.
New Delhi: Department Of Justice has withdrawn its motion against Ranbaxy, says Pharma-news-asia.com.
The motion claimed that Ranbaxy had submitted false and fabricated information to the FDA about the stability of its generic medications.
But there is still a case on relating to an FDA alert on 30 Ranbaxy drugs.
The sale of more than 30 generic medicines made in two OF Ranbaxy's Indian factories stand banned in the US because of deficiencies in manufacturing processes.
The Justice Department's decision has come as a relief to the pharma major.
Comments
0 comment